Augustine Therapeutics Welcomes New Chief Scientific Officer
Augustine Therapeutics has made an exciting addition to its leadership team by appointing Rie Schultz Hansen, PhD, as its Chief Scientific Officer. This move shows the company's commitment to advancing its innovative programs, particularly the lead HDAC6 inhibitor, AGT-100216, aimed at treating Charcot-Marie-Tooth Disease.
Strengthening the Executive Team
Rie Schultz Hansen brings over 20 years of experience in drug discovery and development, especially in the areas of cardio-metabolic and inflammation-driven diseases. Before her role at Augustine, she was Chief Scientific Officer at Aelin Therapeutics, where she played a pivotal role in developing a degrader platform that targets disease-causing proteins. Her entrepreneurial spirit led her to advance AI/ML-based solutions, showcasing her ability to innovate in the biotech space.
Research Expansion with New Subsidiary
As part of its growth strategy, Augustine Therapeutics has also established a new subsidiary in Denmark, named Augustine Therapeutics Denmark ApS. This subsidiary will serve as the company's hub for research focusing on cardio-metabolic diseases, allowing for enhanced collaboration and innovation in a region recognized for its strength in medical research.
Expertise and Background of Rie Schultz Hansen
Rie has an impressive history at Zealand Pharma, where she held multiple significant roles, including Innovation Officer and VP of Discovery and Innovation. Her experience managing preclinical projects until their submission for clinical trials positions her well to lead Augustine's promising pipeline. She has also had ongoing collaborations with academia, serving in various capacities that further solidify her reputation in the scientific community.
Future Directions for Augustine Therapeutics
Gerhard Koenig, PhD, CEO of Augustine Therapeutics, expressed his enthusiasm about Rie's appointment, stating that her leadership will be crucial for progressing AGT-100216 through crucial clinical trials. He emphasized the importance of her expertise, particularly as the company expands its research into neurodegenerative and cardio-metabolic indications. The innovative focus at Augustine is built around developing selective HDAC6 inhibitors that can operate while maintaining beneficial functions.
Rie’s Vision for the Company
Reflecting on her new role, Rie Schultz Hansen noted the pivotal stage Augustine is entering. With groundbreaking approaches to target HDAC6, she aims to maximize the potential of the company’s pipeline as it progresses into clinical phases. The new Danish subsidiary will serve as a significant resource in leveraging local talents and research capabilities.
About Augustine Therapeutics
Augustine Therapeutics is dedicated to pioneering therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases. The company's approach to selectively inhibit HDAC6 is distinct, allowing the beneficial functions of the enzyme to be preserved. AGT-100216 represents the first of these innovative products aimed at treating Charcot-Marie-Tooth disease along with other significant conditions.
Frequently Asked Questions
What is the significance of Rie Schultz Hansen's appointment?
Rie's expertise in drug development will enhance Augustine's ability to advance its therapeutic programs and clinical trials.
What role will the new subsidiary in Denmark play?
It will serve as a research hub for cardio-metabolic conditions, fostering enhanced collaboration and innovation.
How does AGT-100216 work?
AGT-100216 is designed to selectively inhibit HDAC6, aiming to treat Charcot-Marie-Tooth disease by targeting specific mechanisms in disease pathways.
What is Augustine Therapeutics focused on?
The company focuses on developing therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases.
How long has Rie Schultz Hansen been in the biotech industry?
Rie has over 20 years of experience in drug discovery and development across various therapeutic areas.
